Key terms
About ALT
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ALT news
Yesterday
9:05am ET
Altimmune has ‘ideal lifestyle anti-obesity drug,’ says B. Riley
Yesterday
8:00am ET
Analysts Are Bullish on Top Healthcare Stocks: Moderna (MRNA), Altimmune (ALT)
Yesterday
7:30am ET
Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), Kiora Pharmaceuticals (KPRX) and Actinium Pharmaceuticals (ATNM)
Mar 27
5:25pm ET
Buy Rating Affirmed for Altimmune as Pemvidutide Shows Promising Weight Loss and Lean Mass Preservation
Mar 27
3:40pm ET
Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Altimmune (ALT)
Mar 27
3:35pm ET
Piper continues to be bullish on Altimmune
Mar 27
9:41am ET
Unusually active option classes on open March 27th
Mar 27
7:09am ET
Altimmune reports Q4 EPS (54c), consensus (43c)
Mar 25
8:00am ET
Options Volatility and Implied Earnings Moves This Week, March 26 – March 28, 2024
Mar 05
9:39am ET
Altimmune Stock (NASDAQ:ALT) Rides Volatility Wave Despite Promising Pipeline
Feb 29
10:57am ET
Biotech Alert: Searches spiking for these stocks today
Feb 29
10:57am ET
Biotech Alert: Searches spiking for these stocks today
Feb 28
11:59am ET
Biotech Alert: Searches spiking for these stocks today
Feb 28
11:59am ET
Biotech Alert: Searches spiking for these stocks today
Feb 27
11:25am ET
Altimmune call volume above normal and directionally bullish
Feb 26
2:45pm ET
Altimmune’s Pemvidutide Poised for Market Success: A Buy Rating with a $25 Price Target
Feb 26
10:16am ET
Madrigal Pharmaceuticals downgraded to Sell at B. Riley after competitor data
Feb 26
9:40am ET
Analysts Conflicted on These Healthcare Names: Cogent Biosciences (COGT) and Altimmune (ALT)
Feb 26
9:40am ET
Unusually active option classes on open February 26th
Feb 15
8:55am ET
Altimmune (ALT) Gets a Buy from Piper Sandler
Feb 13
10:35pm ET
Buy Rating for Altimmune Backed by Pemvidutide’s Promise and Market Potential
Feb 13
2:44pm ET
Altimmune short report includes ‘factual inconsistencies,’ says B. Riley
Feb 09
2:25pm ET
Altimmune call volume above normal and directionally bullish
Feb 06
3:15pm ET
Altimmune’s Pemvidutide Shows Promising Outlook in NASH and Obesity Markets: A Strong Buy Rating
Jan 24
4:43am ET
Altimmune reinstated with a Neutral at Goldman Sachs
Jan 24
2:38am ET
Maintaining Hold on Altimmune: Balancing Phase 2 Promise with Strategic Partnership Needs
Jan 22
2:10pm ET
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), 10x Genomics (TXG) and Altimmune (ALT)
Jan 12
8:30am ET
Analysts Conflicted on These Healthcare Names: Legend Biotech (LEGN), Altimmune (ALT) and Apellis Pharmaceuticals (APLS)
Jan 10
9:40am ET
Unusually active option classes on open January 10th
Jan 08
12:35am ET
Buy Rating for Altimmune’s Pemvidutide: A Promising Candidate for NASH Resolution and Fibrosis Improvement
Jan 02
12:13pm ET
The biotech stocks to own in 2024, according to Piper Sandler
No recent press releases are available for ALT
ALT Financials
Key terms
Ad Feedback
ALT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ALT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range